We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Peptide From Violets May Help To Treat Glioblastoma

Peptide From Violets May Help To Treat Glioblastoma

Peptide From Violets May Help To Treat Glioblastoma

Peptide From Violets May Help To Treat Glioblastoma

Credit: Artiom Vallat/ Unsplash
Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Peptide From Violets May Help To Treat Glioblastoma"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A circular peptide derived from violets could lead to new approaches in treating glioblastoma, a highly aggressive form of brain cancer.

Researchers report that cyclotides, small circular proteins produced by violets increase the power of TMZ, a chemotherapeutic agent, in killing human glioblastoma cancer cells.

Glioblastoma is a fatal type of brain cancer of adults and children with a median survival time of 9-16 months from diagnosis. Half of the tumors are resistant to the only FDA-approved treatment, TMZ, and the remainder quickly evolve resistance to this chemotherapy. Combining cyclotides with TMZ can increase the ability of TMZ to kill glioblastoma cells up to eight-fold, researchers report.

“We think we are on a path that could lead to better treatment of glioblastoma in the future,” reports Dillard University Professor Samantha Gerlach, lead author of the report published last week in the Journal of Natural Products.

The biggest hurdle faced by researchers working in the laboratories based in Wyoming is extracting enough of the compounds from violets to test. Kilograms of violets are needed to yield a tiny dose.

“Our cell culture studies, though encouraging, are far from being useful in a clinical setting,” cautions Dr. Paul Alan Cox, Director of the non-profit Brain Chemistry Labs in Jackson Hole. “Just extracting enough cyclotides to test in mice will take months.”

Despite these technical obstacles, the research team remains undaunted. “Patients, particularly children, diagnosed with glioblastoma have few options,” says Dr. Samantha Gerlach. “Our goal is to eventually provide new hope to glioblastoma patients and their families.”

Reference: Gerlach SL, Dunlop RA, Metcalf JS, Banack SA, Cox PA. Cyclotides chemosensitize glioblastoma cells to temozolomide. J Nat Prod. 2022. doi: 10.1021/acs.jnatprod.1c00595

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.